Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 8/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.47 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.47 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.47 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.47 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076323 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL980093 | 0.86 | MEN1 (0.75) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL19164320 | 0.82 | MEN1 (0.69) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL27404902 | 0.82 | CYP3A4 (0.69) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL3258819 | 0.81 | MEN1 (0.69) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL3258817 | 0.81 | MEN1 (0.69) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL2566292 | 0.81 | TAAR1 (0.97) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL22461447 | 0.80 | CYP3A4 (0.66) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL22445693 | 0.80 | CYP3A4 (0.66) | CYP3A4MEN1CYP2D6KMT2ATAAR1 | |
| SCHEMBL22445614 | 0.80 | DRD1 (0.68) | CYP3A4MEN1CYP2D6KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191151-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-2620428-B1 | ASYMMETRIC AUXILIARY GROUP | WAVE LIFE SCIENCES LTD (SG) | 2019-05-22 | — | — | EP | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130178612-A1 | CHIRAL AUXILIARIES | CHIRALGEN, LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20130178612-A1 | CHIRAL AUXILIARIES | CHIRALGEN, LTD. (JP) | 2013-07-11 | — | — | US | disclosed |
| CN-101268054-B | Substituted 4-phenyltetrahydroisoquinolines, process for their production, their use as medicaments and medicaments comprising them | SANOFI AVENTIS | 2012-08-22 | — | — | CN | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-7858560-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265122-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| CN-101023060-A | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, their use as a medicament, and a medicament containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | CN | disclosed |
| CN-1798737-A | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | AVENTIS PHARMA GMBH (DE) | 2006-07-05 | — | — | CN | disclosed |
| US-20050003558-A1 | Biological sample component purification and differential display | CHIRON CORPORATION (US) | 2005-01-06 | — | — | US | disclosed |
| US-6783929-B1 | COMPRISES POLYAMIDE LIGANDS FOR ENHANCED EFFICIENCY OF PROTEOMICS | CHIRON CORPORATION | 2004-08-31 | — | — | US | disclosed |
| CN-1452623-A | 4-phenyl substd. tetrahydroisoquinolines and therapeutic use thereof | ALBANY MOLECULE RES INC (US) | 2003-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178612-A1 | CHIRAL AUXILIARIES | POLL, PCNA, POLM | CYP3A4 2809/4885MEN1 1259/4885CYP2D6 1627/4885 |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | CYP3A4 3746/4885MEN1 3426/4885CYP2D6 4323/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | CYP3A4 2407/4885MEN1 2624/4885CYP2D6 1823/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | CYP3A4 4002/4885MEN1 2224/4885CYP2D6 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.